Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Thomas R. Staab, II, CFO and Treasurer, will present at the UBS Global Life Sciences Conference on Thursday, September 25, 2008 at 1:00 pm ET in New York City.
The webcast of the presentation will be available on Inspire's web site at www.inspirepharm.com. An archived version of the webcast presentation will also be available through this link for a limited time following the conference.
About Inspire
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire employs a U.S. sales force for the promotion of AzaSite® (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is currently developing products for dry eye, cystic fibrosis and glaucoma. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a registered trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny
Kobin, VP, Investor Relations and
Corporate Communications,
919-941-9777, Ext. 219
or
Media Contact:
BMC
Communications
Dan Budwick, 973-271-6085